Public Offering

EyePoint (EYPT) is undertaking a public offering to raise $150 million, priced on October 14, 2025. The offering includes 11,000,000 shares at $12.00 each and warrants for 1,500,000 shares at $11.999 each. Expected closing is around October 16, 2025. Underwriters have the option to purchase 1,875,000 more shares. Net proceeds will fund DURAVYU’s clinical development for wet AMD and DME, other pipeline projects, and general corporate expenses. The offering will be dilutive if warrants and the underwriter option are fully exercised.

Spyre Therapeutics (SYRE) announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, projecting $275.0 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 2,229,729 shares. The offering is expected to close around October 15, 2025, pending customary conditions. Funds will support research and development of antibody therapies for IBD and other immune-mediated conditions. Jefferies, TD Securities, Leerink Partners, and Stifel acted as joint book-running managers.

Hycroft Mining Holding Corporation (HYMC) announced a public offering of 23,076,924 Class A common stock shares at $6.50 per share, expecting $150 million in gross proceeds. These funds will be used to expand exploration and drilling at the Hycroft Mine in Nevada and to reduce debt. The offering, led by BMO Capital Markets, is expected to close on October 14, 2025. Hycroft focuses on developing its Nevada mine, one of the world’s largest precious metals deposits, while exploring high-grade silver systems.

AAR CORP. (NYSE: AIR) announced the pricing of a public offering of 3,000,000 shares of common stock at $83.00 per share. Underwriters have an option to purchase up to 450,000 additional shares. Net proceeds, estimated at $239 million (potentially $274.9 million with the option), will primarily repay debt under its revolving credit facility and for general corporate purposes, including potential acquisitions. Goldman Sachs, Jefferies, and RBC Capital Markets are the joint lead book-running managers. The offering is expected to close around October 2, 2025.

bioAffinity Technologies announced the completion of a public offering, generating $4.8 million in gross proceeds. The offering included shares of common stock and pre-funded warrants. WallachBeth Capital, LLC served as the placement agent. bioAffinity focuses on non-invasive cancer diagnostics, including CyPath® Lung, a Laboratory Developed Test for early lung cancer detection. The company addresses the growing precision diagnostics market with a focus on improving patient outcomes through early diagnosis. The announcement contains forward-looking statements subject to risks detailed in SEC filings.

Soligenix, Inc. (SNGX) announced a public offering of 5,555,560 shares of common stock (or equivalents) with warrants at $1.35 per share/warrant. The warrants are immediately exercisable at $1.35, expiring in five years. Existing warrants for 1,162,064 shares will be amended to the same price and expiration. The offering, expected to close around September 29, 2025, aims to raise $7.5 million, which will fund R&D, commercialization, and general corporate needs. A.G.P./Alliance Global Partners is the sole placement agent. This offering is under an effective SEC registration statement.

Mirion Technologies (NYSE: MIR) announced the pricing of an upsized public offering of 17.3 million shares of Class A common stock at $21.35 per share, aiming to raise approximately $356.2 million. Simultaneously, they priced a $325 million convertible senior notes offering. Proceeds will fund capped call transactions related to the notes and the acquisition of Paragon Energy Solutions. The offerings are expected to close on September 30, 2025. Goldman Sachs and Evercore ISI are leading the common stock offering. These moves support Mirion’s growth strategy in radiation safety, science, and medicine.

Wellgistics Health (WGRX) announced a $5 million public offering of 7,142,862 shares and warrants priced at $0.70 per share. Warrants are exercisable at $0.70 immediately and expire in five years. The offering, managed by H.C. Wainwright & Co., is expected to close around September 29, 2025. Proceeds will fund working capital, operating expenses, R&D, and potential acquisitions. The offering entails significant shareholder dilution.

Reviva Pharmaceuticals (RVPH) announced a $9 million public offering of 27 million shares/equivalents, plus Series E & F warrants, priced at $0.335 per share. Proceeds will fund R&D and corporate purposes. The Series E warrants expire in 5 years, Series F in 12 months, both exercisable at $0.335. Expected closing is around Sept. 22, 2025. The offering, led by A.G.P./Alliance Global Partners, may lead to shareholder dilution, with potential for 54 million additional warrant shares.

StubHub Holdings, the leading global secondary ticketing marketplace, announced the pricing of its IPO at $23.50 per share, offering over 34 million shares. Trading on the NYSE under “STUB” begins September 17, 2025. J.P. Morgan and Goldman Sachs are leading the offering, which reflects strong investor confidence in the live events sector. StubHub, operating in North America and internationally via viagogo, serves customers globally in multiple languages and currencies, facilitating ticket sales for diverse live events. Its success hinges on navigating competition and leveraging technology.